Ridgetech Bets on Digital 'Dual-Engine' to Reshape China's Pharma Supply

HANGZHOU, China – March 04, 2026 – Ridgetech, Inc. (Nasdaq: RDGT) today unveiled an ambitious "dual-engine" growth strategy for 2026, signaling a decisive move to integrate its traditional pharmaceutical wholesale operations with a powerful digital B2B platform. The plan, which aims to create a deeply synergistic online and offline ecosystem, positions the company to compete more aggressively in China's rapidly digitizing and fiercely competitive healthcare market.

A Strategic Pivot in a Transforming Market

This move comes as China's healthcare industry undergoes a profound transformation. The market, already the world's second-largest, is on a steep growth trajectory, projected to exceed US$126 billion by 2030. This expansion is fueled by an aging demographic, rising incomes, and the increasing prevalence of chronic diseases. More importantly, the sector is being reshaped by the "Healthy China 2030" national initiative, a sweeping government blueprint designed to enhance healthcare quality, affordability, and access. A core tenet of this initiative is the aggressive push for digital-intelligent transformation across the entire pharmaceutical industry, with a goal of achieving full coverage by 2030.

This policy has ignited a race among distributors to modernize supply chains, enhance efficiency, and leverage data to better serve pharmacies, clinics, and hospitals. Against this backdrop, Ridgetech's strategy is not just an internal corporate plan but a calculated response to a fundamental shift in the industry, where digital prowess is becoming as critical as logistical reach.

Forging a New Identity from Wholesale Roots

Ridgetech's announcement is the culmination of a significant corporate restructuring. The company, which operated for years as China Jo-Jo Drugstores, officially rebranded in February 2025. This was more than a name change; it marked a strategic pivot. In a decisive move, the company divested its legacy brick-and-mortar retail drugstore business and simultaneously acquired Allright (Hangzhou) Internet Technology Co., Ltd., a fast-growing pharmaceutical wholesale and B2B technology firm. This transaction effectively transformed Ridgetech into a more focused, asset-light wholesale distributor.

Early financial results suggest the pivot is bearing fruit. For the fiscal year ending March 31, 2025, the company reported a net income of $10.20 million from its continuing wholesale operations, a stark turnaround from a net loss of $4.23 million the prior year. This shift to profitability underscores the potential of its new wholesale-centric model, setting a positive foundation for the more ambitious integration strategy now being launched.

The 'Dual-Engine' Blueprint for Growth

The 2026 strategy formalizes this new identity, centered on two core growth engines working in concert. The first engine is Zhejiang Jiuxin Medicine Co., Ltd., Ridgetech's established offline pharmaceutical wholesale distribution platform, which serves as the strategic cornerstone and supply chain hub. The second, and arguably more dynamic, engine is the Allright B2B platform, tasked with driving digital expansion and market penetration.

The company has set aggressive targets for Allright, aiming to expand its customer base to over 300,000 entities, achieve a 30% year-on-year increase in new B2B customers, and push its online business penetration rate above 30% in 2026. The true power of the strategy lies in their integration. Ridgetech plans to systematically onboard Jiuxin Medicine's extensive product portfolio onto the Allright platform. This is designed to streamline procurement and sales, reduce costly distribution layers, and dramatically improve operational agility. The company envisions a virtuous cycle where "procurement drives sales and sales guide procurement," using data from the Allright platform to inform inventory strategies and category planning for the entire wholesale operation.

Racing Against Digital Giants and Industry Titans

Ridgetech is not innovating in a vacuum. Its dual-engine strategy is a direct response to the intense competitive pressures from both established giants and nimble tech players. State-owned behemoths like Sinopharm Group and Shanghai Pharmaceuticals have been heavily investing in their own digital infrastructure, leveraging AI and extensive distribution networks to maintain dominance. Meanwhile, e-commerce titans like JD Health and Alibaba Health have made significant inroads into the pharmaceutical B2B and B2C space, operating massive online platforms that connect thousands of suppliers and buyers.

For instance, JD Health's "JD Medicine Procurement" platform and Jointown Pharmaceutical Group's supplier-collaboration platform are clear indicators that the future of distribution is digital and platform-based. Ridgetech’s focus on integrating its established supply chain strengths with a modern digital front-end is its bid to carve out a defensible niche in this crowded field, offering a blend of traditional reliability and digital efficiency to independent pharmacies and clinics that may be underserved by larger players.

In the company's announcement, Interim CEO and CFO Mr. Frank Zhao framed the strategy as a direct response to industry dynamics. "In recent years, as demographic trends, policy orientation, and emerging technologies continue to reshape China's pharmaceutical and healthcare industry, the sector has entered a critical phase of profound transformation," he stated. "We remain firmly committed to our strategic positioning—strengthening foundations while advancing innovation... to guide the Company toward high-quality development."

The success of this dual-engine approach will depend on flawless execution. Integrating the data and processes of an established offline wholesaler with a fast-moving online platform is a complex operational challenge. However, if successful, the strategy could enable Ridgetech to create a highly efficient, data-driven distribution system that accurately matches supply with demand. By doing so, the company aims not only to create greater value for its shareholders but also to play a more significant role in fulfilling the ambitious goals of the "Healthy China 2030" initiative, delivering quality medicines to a market of 1.4 billion people.